Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Tomorrow Today show: AI, enzymes and the future of medicine
heltzennutraceuticalsmedicinepress clippingsvideopodcastNCT
Tomorrow Today show: AI, enzymes and the future of medicineNovember 3, 2026
WTR fireside chat & report: CEO Discusses the Road to Commercialization
heltzennutraceuticalspress clippingsvideoNCT
WTR fireside chat & report: CEO Discusses the Road to CommercializationOctober 29, 2026
Benzinga: The Next Industrial Revolution May Come From Biology
investorpress clippings
Benzinga: The Next Industrial Revolution May Come From BiologyOctober 28, 2026
Fireside chat with Water Tower Research - tomorrow at 11AM EST
heltzenpress releaseinvestor
CEO to discuss commercialization, key milestones, and potential catalysts in fireside chat with WTROctober 21, 2026
Damien Perriman on Balancing the Future podcast
press clippingspodcastperrimanNCT
Balancing the Future podcast: Cell-free bioengineering - the new chemical manufacturing frontierOctober 20, 2026
Mashable: AI is accelerating Drug Discovery. Can manufacturing keep up?
investorpress clippingsNCT
Mashable: AI is accelerating Drug Discovery. Can manufacturing keep up?October 19, 2026
Pix11 "Top Leaders" featuring EXOZ CEO, Heltzen
heltzeninvestorpress clippingsvideoNCT
Pix11 News: Reinventing How Medicine Is MadeOctober 8, 2026
Slack Capital: eXoZymes’ Path to Computational Biomanufacturing
investorpress clippings
Slack Capital: eXoZymes’ Path to Computational BiomanufacturingOctober 7, 2026
Heltzen on Grow Everything podcast, episode #201
heltzennutraceuticalspress clippingsvideoNCT
Grow Everything podcast: Out of Cell Experience - Heltzen Drives Pure ChemistryOctober 2, 2026
WTR: INITIATION OF COVERAGE REPORT
investorpress clippings
WTR: Converting Cell-Free Science into a Scalable and Repeatable Commercial OpportunityOctober 1, 2026
Previous page
Page 1 of 16
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark